Last reviewed · How we verify
pentoxifylline (Trental SR®)
Pentoxifylline increases blood flow by improving red blood cell flexibility and reducing blood viscosity.
Pentoxifylline increases blood flow by improving red blood cell flexibility and reducing blood viscosity. Used for Symptomatic relief of intermittent claudication.
At a glance
| Generic name | pentoxifylline (Trental SR®) |
|---|---|
| Sponsor | Al-Azhar University |
| Drug class | xanthine derivative |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Pentoxifylline works by inhibiting the enzyme phosphodiesterase, which breaks down cyclic AMP, a molecule that helps to relax blood vessels and improve blood flow. This leads to improved oxygen delivery to tissues and reduced inflammation.
Approved indications
- Symptomatic relief of intermittent claudication
Common side effects
- Nausea
- Headache
- Dizziness
- Diarrhea
- Abdominal pain
Key clinical trials
- Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease (PHASE3)
- Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis (PHASE3)
- Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pentoxifylline (Trental SR®) CI brief — competitive landscape report
- pentoxifylline (Trental SR®) updates RSS · CI watch RSS
- Al-Azhar University portfolio CI